Patents by Inventor Klaus Seibel

Klaus Seibel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20100227896
    Abstract: Vitamin PP compounds and compounds with anti-pellagra activity such as nicotinic acid and nicotinamide are useful for the reduction, elimination, and prevention of side-effects of immunosuppressive and anti-cancer chemotherapy and diagnosis, especially those induced by the use of substituted pyridine carboxamides of formula I. Combinations containing compounds of formula I and the vitamin PP compounds and compounds with anti-pellagra activity are provided for these chemotherapies and diagnoses.
    Type: Application
    Filed: May 13, 2010
    Publication date: September 9, 2010
    Applicant: ASTELLAS DEUTSCHLAND GMBH
    Inventors: Elfi Biedermann, Max Hasmann, Roland Löser, Benno Rattel, Friedemann Reiter, Barbara Schein, Isabel Schemainda, Klaus Seibel, Klaus Vogt, Katja Wosikowski
  • Patent number: 7320993
    Abstract: The invention relates to new pyridylalkane, alkene, and alkine acid amides substituted with an aryl and/or heteroaryl residue according to the general formula (I), with a saturated or one or several-fold unsaturated hydrocarbon residue in the carboxylic acid group, methods for the synthesis of these compounds, medicaments containing these and their production as well as their therapeutic use, especially as cytostatic agents and immunosuppressive agents, for example in the treatment or prevention of various types of tumors and control of immune reactions such as autoimmune diseases.
    Type: Grant
    Filed: June 16, 2000
    Date of Patent: January 22, 2008
    Assignee: Astellas Deutschland GmbH
    Inventors: Elfi Biedermann, Max Hasmann, Roland Löser, Benno Rattel, Friedemann Reiter, Barbara Schein, Klaus Seibel, Klaus Vogt, Katja Wosikowski, Isabel Schemainda
  • Patent number: 7276524
    Abstract: The invention relates to new pyridyl alkane acid amides according to general formula (I) as well as methods for their production, medicaments containing these compounds as well as their medical use, especially in the treatment of tumors or for immunosuppression
    Type: Grant
    Filed: October 10, 2003
    Date of Patent: October 2, 2007
    Assignee: Astellas Deutschland GmbH
    Inventors: Elfi Biedermann, Max Hasmann, Roland Löser, Benno Rattel, Friedemann Reiter, Barbara Schein, Klaus Seibel, Klaus Vogt
  • Publication number: 20070219197
    Abstract: The present invention relates to new pyridine compounds, methods for their production, medicaments containing these compounds as well as their use, especially in the treatment of tumor conditions and/or as cytostatic agents or as immunosuppressive agents.
    Type: Application
    Filed: December 7, 2006
    Publication date: September 20, 2007
    Applicant: Astellas Pharma GmbH
    Inventors: Elfi Biedermann, Max Hasmann, Roland Loser, Benno Rattel, Friedemann Reiter, Barbara Schein, Klaus Seibel, Klaus Vogt
  • Patent number: 7241745
    Abstract: The invention relates to a new pyridyl alkene and pyridyl alkine acid amides according to the general formula (I) as well as methods for their production, medicaments containing these compounds as well as their medical use, especially in the treatment of tumors or for immunosuppression.
    Type: Grant
    Filed: August 5, 2002
    Date of Patent: July 10, 2007
    Assignee: Astellas Pharma GmbH
    Inventors: Elfi Biedermann, Max Hasmann, Roland Löser, Benno Rattel, Friedemann Reiter, Barbara Schein, Klaus Seibel, Klaus Vogt
  • Publication number: 20070142377
    Abstract: The invention relates to a new pyridyl alkene and pyridyl alkine acid amides according to the general formula (I) as well as methods for their production, medicaments containing these compounds as well as their medical use, especially in the treatment of tumors or for immunosuppression.
    Type: Application
    Filed: February 26, 2007
    Publication date: June 21, 2007
    Inventors: Elfi Biedermann, Max Hasmann, Roland Loser, Benno Rattel, Friedemann Reiter, Barbara Schein, Klaus Seibel, Klaus Vogt
  • Patent number: 7192967
    Abstract: The invention relates to new pyridylalkane, alkene, and alkine carboxamides substituted with an imide with a saturated or one or several-fold unsaturated hydrocarbon residue in the carboxylic acid group according to general formula (I), wherein the residue E is a cyclic imide, methods for the production of these compounds, medicaments containing these and their production as well as their therapeutic use, especially as cytostatic agents and immunosuppressive agents, for example in the treatment or prevention of various types of tumors, inhibition of abnormal cell growth and control of immune reactions, for example autoimmune diseases.
    Type: Grant
    Filed: June 16, 2000
    Date of Patent: March 20, 2007
    Assignee: Astellas Pharma GmbH
    Inventors: Elfi Biedermann, Max Hasmann, Roland Löser, Benno Rattel, Friedemann Reiter, Barbara Schein, Klaus Seibel, Klaus Vogt, Katia Wosikowski, Isabel Schemainda
  • Patent number: 6903118
    Abstract: The invention relates to new piperazinyl-substituted pyridylalkane, alkene, and alkine acid amides substituted with saturated or one or several-fold unsaturated hydrocarbon residue in the carboxylic acid group according to the general formula (I) as well as methods for the production of these compounds, medicaments containing these and their production as well as their therapeutic use, especially as cytostatic agents and immunosuppressive agents, for example in the treatment or prevention of various types of tumors and control of immune reactions such as autoimmune diseases.
    Type: Grant
    Filed: June 16, 2000
    Date of Patent: June 7, 2005
    Assignee: Klinge Pharma GmbH
    Inventors: Elfi Biedermann, Max Hasmann, Roland Löser, Benno Rattel, Friedemann Reiter, Barbara Schein, Klaus Seibel, Klaus Vogt, Katja Wosikowski, Isabel Schemainda
  • Publication number: 20040176605
    Abstract: The invention relates to new pyridyl alkane acid amides according to general formula (I) as well as methods for their production, medicaments containing these compounds as well as their medical use, especially in the treatment of tumors or for immunosuppression.
    Type: Application
    Filed: October 10, 2003
    Publication date: September 9, 2004
    Applicant: Klinge Pharma GmbH
    Inventors: Elfi Biedermann, Max Hasmann, Roland Loser, Benno Rattel, Friedemann Reiter, Barbara Schein, Klaus Seibel, Klaus Vogt
  • Publication number: 20040029861
    Abstract: The invention relates to the use of pharmacologically valuable pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides according to general formula (I) in the treatment of tumors or for immunosuppression.
    Type: Application
    Filed: July 30, 2002
    Publication date: February 12, 2004
    Applicant: Klinge Pharma GmbH
    Inventors: Elfi Biedermann, Max Hasmann, Roland Loser, Benno Rattel, Friedemann Reiter, Barbara Schein, Klaus Seibel, Klaus Vogt
  • Publication number: 20040009967
    Abstract: The invention relates to new pyridyl alkane acid amides according to general formula (I) as well as methods for their production, medicaments containing these compounds as well as their medical use, especially in the treatment of tumors or for immunosuppression.
    Type: Application
    Filed: July 30, 2002
    Publication date: January 15, 2004
    Applicant: Klinge Pharma GmbH
    Inventors: Elfi Biedermann, Max Hasmann, Roland Loser, Benno Rattel, Friedemann Reiter, Barbara Schein, Klaus Seibel, Klaus Vogt
  • Publication number: 20030162972
    Abstract: The invention relates to new pyridyl alkane acid amides according to general formula (I) as well as methods for their production, medicaments containing these compounds as well as their medical use, especially in the treatment of tumors or for immunosuppression.
    Type: Application
    Filed: August 5, 2002
    Publication date: August 28, 2003
    Applicant: Klinge Pharma GmbH
    Inventors: Elfi Biedermann, Max Hasmann, Roland Loser, Benno Rattel, Friedemann Reiter, Barbara Schein, Klaus Seibel, Klaus Vogt
  • Patent number: 6593344
    Abstract: The invention relates to new piperidinyl-substituted pyridyl carboxamides of the general formula (I), wherein the structure element E has meanings (E1) or (E2) and whereby the heterocyclic ring can optionally have a double bond. These substances have especially high cytostatic activities and pronounced immunosuppressive properties which make them suitable for therapeutic treatment in broad tumor spectrum.
    Type: Grant
    Filed: June 16, 2000
    Date of Patent: July 15, 2003
    Assignee: Klinge Pharma GmbH
    Inventors: Elfi Biedermann, Max Hasmann, Roland Löser, Benno Rattel, Friedemann Reiter, Barbara Schein, Klaus Seibel, Klaus Vogt, Katja Wosikowski, Isabel Schemainda
  • Patent number: 6506572
    Abstract: New biologically active compounds are described which inhibit the cellular formation of niacinamide mononucleotide, and essential intermediate of the NAD(P) biosynthesis in the cell. These compounds can represent the active ingredient of a pharmaceutical composition for the treatment of cancers, leukaemias or for immunosuppression. Furthermore, screening methods are described as a tool for detecting the above active compounds, and for examination of a given cell type for its dependency on niacinamide as a precursor for NAD synthesis.
    Type: Grant
    Filed: August 23, 2001
    Date of Patent: January 14, 2003
    Assignee: Klinge Pharma GmbH
    Inventors: Elfi Biedermann, Rolf Eisenburger, Max Hasmann, Roland Löser, Benno Rattel, Friedemann Reiter, Barbara Schein, Isabel Schemainda, Michael Schulz, Klaus Seibel, Klaus Vogt, Katja Wosikowski
  • Publication number: 20020160968
    Abstract: New biologically active compounds are described which inhibit the cellular formation of niacinamide mononucleotide, and essential intermediate of the NAD(P) biosynthesis in the cell. These compounds can represent the active ingredient of a pharmaceutical composition for the treatment of cancers, leukaemias or for immunosuppression. Furthermore, screening methods are described as a tool for detecting the above active compounds, and for examination of a given cell type for its dependency on niacinamide as a precursor for NAD synthesis.
    Type: Application
    Filed: August 23, 2001
    Publication date: October 31, 2002
    Applicant: Klinge Pharma GmbH
    Inventors: Elfi Biedermann, Rolf Eisenburger, Max Hasmann, Roland Loser, Benno Rattel, Friedemann Reiter, Barbara Schein, Isabel Schemainda, Michael Schulz, Klaus Seibel, Klaus Vogt, Katja Wosikowski
  • Patent number: 6451816
    Abstract: The invention relates to the use of pharmacologically valuable pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides according to general formula (I) in the treatment of tumors or for immunosuppression.
    Type: Grant
    Filed: December 18, 1998
    Date of Patent: September 17, 2002
    Assignee: Klinge Pharma GmbH
    Inventors: Elfi Biedermann, Max Hasmann, Roland Löser, Benno Rattel, Friedemann Reiter, Barbara Schein, Klaus Seibel, Klaus Vogt
  • Patent number: 6444823
    Abstract: The invention relates to new pyridyl alkane acid amides according to general formula (I) as well as methods for their production, medicaments containing these compounds as well as their medical use, especially in the treatment of tumors or for immunosuppression.
    Type: Grant
    Filed: December 18, 1998
    Date of Patent: September 3, 2002
    Assignee: Klinge Pharma GmbH
    Inventors: Elfi Biedermann, Max Hasmann, Roland Löser, Benno Rattel, Friedemann Reiter, Barbara Schein, Klaus Seibel, Klaus Vogt
  • Patent number: 5149865
    Abstract: The invention relates to p-oxibenzoic acid derivatives of the general formula (1) where: ##STR1## their diastereomers and enantiomers in pure form or as mixture of stereoisomeric forms and their physiologically compatible salts, a process for the preparation thereof and the use thereof for preparing drugs with hypolipemic effect.
    Type: Grant
    Filed: December 20, 1991
    Date of Patent: September 22, 1992
    Assignee: Klinge Pharma GmbH
    Inventors: Friedemann Reiter, Helmut Grill, Hans-Helmut Henschel, Michael Schliack, Klaus Seibel, Roland Loser, Gerhard Lang
  • Patent number: 4778925
    Abstract: Para substituted benzoic acid derivatives of general formula (1) ##STR1## and their physiologically compatible salts, where R.sup.1 may be H, isopropyl, t-butyl p0 X may be ##STR2## and R.sup.2 may be --OH, --OR', where R' is a linear or branched, saturated or unsaturated C.sub.1 to C.sub.3 alkylmoiety, or a --NHCH.sub.2 COOH-- group, have hypolipedemic activity. They may be obtained by known methods either from the corresponding unsaturated ketones or from saturated hydroxycompounds, where the esterified benzoic acid moiety may be saponified or converted to a carboxymethylamide.
    Type: Grant
    Filed: May 22, 1987
    Date of Patent: October 18, 1988
    Assignee: Klinge Pharma GmbH
    Inventors: Helmut Grill, Friedemann Reiter, Michael Schliack, Roland Loser, Klaus Seibel
  • Patent number: 4663354
    Abstract: The use of etilefrin or etilefrin pivalate in the long term treatment of circulatory disorders not due to hypotonia, such as for example peripheral arterial stenoses, leads surprisingly to a continuous stable rise in systolic blood pressure and blood pressure amplitude and an improved cardiac output, without affecting the diastolic blood pressure or the cardiac frequency. The pharmaceutical effect is enhanced by using etilefrin in combination with an extract of horse chestnut seeds in a long term treatment.
    Type: Grant
    Filed: April 19, 1985
    Date of Patent: May 5, 1987
    Assignee: Klinge Pharma GmbH
    Inventors: Alois Niederhauser, Klaus Seibel